UPDATE: PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for patient enrollment in Phase III Breast Cancer Trial
06 nov. 2024 15h42 HE
|
Predicine
HAYWARD, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, is pleased to announce the publication of a landmark study in The New England Journal of...
PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche’s Phase III Itovebi Breast Cancer Trial
04 nov. 2024 12h28 HE
|
Predicine
PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA’s approval of Inavolisib in the U.S. on...
Predicine to Present 9 Liquid Biopsy Studies at ASCO 2024
22 mai 2024 00h11 HE
|
Predicine
HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 9 ctDNA studies at ASCO 2024,...
UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
11 avr. 2024 23h07 HE
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
05 avr. 2024 16h21 HE
|
Predicine
Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
05 avr. 2024 16h10 HE
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
05 avr. 2024 02h08 HE
|
Predicine
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting...
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
08 janv. 2024 12h01 HE
|
Predicine
Collaboration Utilizing PredicineCARE™ Urine cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC
11 déc. 2023 15h12 HE
|
Predicine
HAYWARD, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib...
Predicine announces six studies showcasing MRD and liquid biopsy innovations at ESMO 2023
17 oct. 2023 13h58 HE
|
Predicine
HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid,...